Risk–benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer

Bibliography

• Daniels K, Mosher WD. Contraceptive methods women have ever used: united States, 1982-2010. Natl Health Stat Report 2013(62):1-15
   Google Scholar
• Jones RK. Beyond birth control: the overlooked benefits of oral contraceptive pills. 2011. Available from: http://www.guttmacher.org/pubs/Beyond-Birth-Control.pdf [Last accessed 1 April 2014]
   Google Scholar
• Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013;22:1931-43
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Epidemiological Studies of Ovarian Cancer. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-14
   PubMed Web of Science ®Google Scholar
• Peragallo Urrutia R, Coeytaux RR, McBroom AJ, et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol 2013;122:380-9
   PubMed Web of Science ®Google Scholar
• Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000;284:72-8
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27
   PubMed Web of Science ®Google Scholar
• Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 2007;47:506-13
   PubMed Web of Science ®Google Scholar
• Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004;190:S5-22
   PubMed Web of Science ®Google Scholar
• Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002;21:8981-93
   PubMed Web of Science ®Google Scholar
• Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705-13
   PubMed Web of Science ®Google Scholar
• Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010;119:7-17
   PubMed Web of Science ®Google Scholar
• Nelson HD, Fu R, Goddard K, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force recommendation. Agency for Healthcare Research and Quality (US), Rockville, MD; 2013
   Google Scholar
• Rebbeck TR. Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer 1999;86:2493-501
   PubMed Web of Science ®Google Scholar
• Balmana J, Diez O, Rubio IT, Cardoso F; ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22:vi31-4
   PubMed Web of Science ®Google Scholar
• Lynch HT, Snyder C, Casey MJ. Hereditary ovarian and breast cancer: what have we learned? Ann Oncol 2013;24:viii83-95
   PubMed Web of Science ®Google Scholar
• Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-16
   PubMed Web of Science ®Google Scholar
• Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer 2013;12:273-7
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Genetic/familial high-risk assessment: colorectal. 2014. Available from: http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf [Last accessed 1 April 2014]
   Google Scholar
• Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009;76:1-18
   PubMed Web of Science ®Google Scholar
• United States Preventive Services Task Force. Risk assessment, genetic counseling and genetic testing for BRCA-related cancer in women. 2013. Available from: http://uspreventiveservicestaskforce.org/uspstf12/brcatest/brcatestfinalrs.htm [Last accessed 1 April 2014]
   Google Scholar
• National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. 2014. Available from: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf [Last accessed 1 April 2014]
   Google Scholar
• Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. Genet Med 2011;13:998-1005
   PubMed Web of Science ®Google Scholar
• Sijmons RH, Greenblatt MS, Genuardi M. Gene variants of unknown clinical significance in Lynch syndrome. An introduction for clinicians. Fam Cancer 2013;12:181-7
   PubMed Web of Science ®Google Scholar
• Eccles DM, Pichert G. Familial non-BRCA1/BRCA2-associated breast cancer. Lancet Oncol 2005;6:705-11
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-99
   PubMed Web of Science ®Google Scholar
• Gaffield ME, Culwell KR, Ravi A. Oral contraceptives and family history of breast cancer. Contraception 2009;80:372-80
   PubMed Web of Science ®Google Scholar
• Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer 2000;7:73-83
   PubMed Web of Science ®Google Scholar
• Isaksson E, von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65:163-9
   PubMed Web of Science ®Google Scholar
• Gupta PB, Proia D, Cingoz O, et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 2007;67:2062-71
   PubMed Web of Science ®Google Scholar
• Szyf M, Pakneshan P, Rabbani SA. DNA methylation and breast cancer. Biochem Pharmacol 2004;68:1187-97
   PubMed Web of Science ®Google Scholar
• Campesi I, Sanna M, Zinellu A, et al. Oral contraceptives modify DNA methylation and monocyte-derived macrophage function. Biol Sex Differ 2012;3:4
   PubMedGoogle Scholar
• Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30
   PubMed Web of Science ®Google Scholar
• Narod SA, Dube MP, Klijn J, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9
   PubMed Web of Science ®Google Scholar
• Haile RW, Thomas DC, McGuire V, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006;15:1863-70
   PubMed Web of Science ®Google Scholar
• Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007;25:3831-6
   PubMed Web of Science ®Google Scholar
• Lee E, Ma H, McKean-Cowdin R, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev 2008;17:3170-8
   PubMed Web of Science ®Google Scholar
• Milne RL, Knight JA, John EM, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005;14:350-6
   PubMed Web of Science ®Google Scholar
• Gronwald J, Byrski T, Huzarski T, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2006;95:105-9
   PubMed Web of Science ®Google Scholar
• Iodice S, Barile M, Rotmensz N, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010;46:2275-84
   PubMed Web of Science ®Google Scholar
• Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013;31:4188-98
   PubMed Web of Science ®Google Scholar
• Kotsopoulos J, Lubinski J, Moller P, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 2014;143:579-86
   PubMed Web of Science ®Google Scholar
• Dhont M. History of oral contraception. Eur J Contracept Reprod Health Care 2010;15(Suppl 2):S12-18
   Google Scholar
• Havrilesky LJ, Gierisch JM, Moorman PG, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep) 2013(212):1-514
   PubMedGoogle Scholar
• Fleming JS, Beaugie CR, Haviv I, et al. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006;247:4-21
   PubMed Web of Science ®Google Scholar
• Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-6
   PubMedGoogle Scholar
• Grimes DA, Economy KE. Primary prevention of gynecologic cancers. Am J Obstet Gynecol 1995;172:227-35
   PubMed Web of Science ®Google Scholar
• Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010;16:631-50
   PubMed Web of Science ®Google Scholar
• Lu KH, Loose DS, Yates MS, et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila) 2013;6:774-81
   PubMed Web of Science ®Google Scholar
• Fernandez E, La Vecchia C, Franceschi S, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998;9:295-300
   PubMed Web of Science ®Google Scholar
• Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 2009;15:489-98
   PubMed Web of Science ®Google Scholar
• Newcomb PA, Pocobelli G, Chia V. Why hormones protect against large bowel cancer: old ideas, new evidence. Adv Exp Med Biol 2008;617:259-69
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Hylind LM, Trimbath JD, et al. Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology 2005;128:1077-80
   PubMed Web of Science ®Google Scholar
• Evans DG, Gaarenstroom KN, Stirling D, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2009;46:593-7
   PubMed Web of Science ®Google Scholar
• Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295-303
   PubMed Web of Science ®Google Scholar
• Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:1547-53
   PubMed Web of Science ®Google Scholar
• Holman LL, Friedman S, Daniels MS, et al. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol 2014;133:283-6
   PubMed Web of Science ®Google Scholar